6FG1

CRYSTAL STRUCTURE OF FAB OF NATALIZUMAB IN COMPLEX WITH FAB OF NAA32.

6FG1 の概要

• エントリーDOI: 10.2210/pdb6fg1/pdb
• 分子名称: HEAVY CHAIN OF FAB NAA32, LIGHT CHAIN OF FAB NAA32, HEAVY CHAIN OF FAB NATALIZUMAB, ... (6 entities in total)
• 機能のキーワード: antibody, immune system
• 由来する生物種: Homo sapiens (HUMAN); 詳細
• タンパク質・核酸の鎖数: 4
• 化学式量合計: 98779.13

構造登録者

Bertrand, T.,Pouzieux, S. (登録日: 2018-01-09, 公開日: 2019-07-24, 最終更新日: 2024-11-13)

主引用文献

Cassotta, A.,Mikol, V.,Bertrand, T.,Pouzieux, S.,Le Parc, J.,Ferrari, P.,Dumas, J.,Auer, M.,Deisenhammer, F.,Gastaldi, M.,Franciotta, D.,Silacci-Fregni, C.,Fernandez Rodriguez, B.,Giacchetto-Sasselli, I.,Foglierini, M.,Jarrossay, D.,Geiger, R.,Sallusto, F.,Lanzavecchia, A.,Piccoli, L.
A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.
Nat. Med., 25:1402-1407, 2019

PubMed Abstract: Natalizumab (NZM), a humanized monoclonal IgG4 antibody to α4 integrins, is used to treat patients with relapsing-remitting multiple sclerosis (MS), but in about 6% of the cases persistent neutralizing anti-drug antibodies (ADAs) are induced leading to therapy discontinuation. To understand the basis of the ADA response and the mechanism of ADA-mediated neutralization, we performed an in-depth analysis of the B and T cell responses in two patients. By characterizing a large panel of NZM-specific monoclonal antibodies, we found that, in both patients, the response was polyclonal and targeted different epitopes of the NZM idiotype. The neutralizing activity was acquired through somatic mutations and correlated with a slow dissociation rate, a finding that was supported by structural data. Interestingly, in both patients, the analysis of the CD4 T cell response, combined with mass spectrometry-based peptidomics, revealed a single immunodominant T cell epitope spanning the FR2-CDR2 region of the NZM light chain. Moreover, a CDR2-modified version of NZM was not recognized by T cells, while retaining binding to α4 integrins. Collectively, our integrated analysis identifies the basis of T-B collaboration that leads to ADA-mediated therapeutic resistance and delineates an approach to design novel deimmunized antibodies for autoimmune disease and cancer treatment.

PubMed: 31501610
DOI: 10.1038/s41591-019-0568-2

実験手法

X-RAY DIFFRACTION (2.03 Å)